Finding a Personalized Approach To Treating Chronic Rejection After Lung Transplantation

By studying the roles of an inflammatory protein and antibodies in chronic rejection after lung transplantation, researchers discover possibilities for new treatments.

11:00 AM

Author | Kylie Urban

drawing of lungs in blue ink on lined paper
Stephanie King

Two new papers examine the processes of lung scarring and chronic rejection of the organ after transplantation, and potential therapies to stop the graft, or transplanted organ and its tissue, from failing.

"Chronic graft failure due to progressive scarring is the number one worry of all transplant physicians with very few means available to stop it," says Vibha Lama, M.D., a lung transplantation physician and professor and vice chair of basic and translational research in internal medicine at Michigan Medicine. "We realize that the way for us to stop it is by discovering why, and how, this scarring develops so that we can offer novel personalized therapies for patients."

Lama is the senior author of the two papers that demonstrate the link between antibodies targeting the donor lung and a particularly aggressive form of chronic rejection after lung transplantation called restrictive allograft syndrome, or RAS.

"It's a very devastating diagnosis because the prognosis is very poor with a high six-month mortality rate and no current therapeutic options," Lama says.

In the study published in JCI Insight, the research team created a mouse lung transplant model that emulates the human disease seen in RAS and show that this specific form of chronic rejection is dependent upon B cells, a type of white blood cells which secrete antibodies. Lama says she then took the mouse model used in the study and applied it to another study, published in American Journal of Transplantation. In that paper, a group of scientists led by Lama, studied interleukin 6, an inflammatory protein, and its role in chronic rejection after lung transplant.

Along with demonstrating how interleukin 6 activates cells that cause lung scarring, they found that targeting this cytokine can be beneficial.

"We show in the mouse model that if the recipient is deficient in interleukin 6, we see much less fibrosis and less chronic rejection," Lama says.

She notes that more research needs to take place, but these studies, along with her previous work, continue to shed additional light on rejection in lung transplant patients.

"The most exciting part is that therapies are available to target both B cells and interleukin 6," Lama says. "The important part for us to understand is which patients with chronic rejection will benefit from them, and these studies moves us forward in that direction. Every transplant patient is unique and we want to have therapy options available that are specific to them."

Papers cited: "Humoral immune responses mediate the development of a restrictive phenotype of chronic lung allograft dysfunction," JCI Insight. DOI: 10.1172/jci.insight.136533.

"Interleukin 6 trans‐signaling is a critical driver of lung allograft fibrosis," American Journal of Transplantation. DOI: 10.1111/ajt.16417.

More Articles About: Lab Notes Lung Disease Lung Transplant Post-Transplant Transplant Surgery Lungs and Breathing
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]


Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Featured News & Stories kids on the floor
Health Lab
Protecting children from poor air quality: 6 things to know
As smoke from Canada's historic wildfires triggers poor air quality alerts across the country, many parents worry about the impact on their child’s health, a national poll suggests. Here, a Michigan Medicine expert provides six ways to help reduce exposure.
Health Lab
Pulmonary embolism deaths, disparities high despite advancements in care
Despite these innovations, a Michigan Medicine study finds that the death rate for pulmonary embolism remains high and unchanged in recent years – more often killing men, Black patients and those from rural areas. The results are published in the Annals of the American Thoracic Society.
Blurry Operating Room
Health Lab
High levels of satisfaction, and low levels of regret, after gender affirming mastectomy
Recent research from the University of Michigan finds that in addition to changing lives, most patients are highly satisfied with their decision to undergo surgery long-term.
emergency room doors
Health Lab
‘Concerning’ CT scans may cause unnecessary hospitalization for some pulmonary embolism patients
Michigan Medicine research finds that some patients with PE, a blood clot in one or more pulmonary arteries, may be hospitalized unnecessarily due to computed tomography, or CT, imaging results rather than clinical risk factors.
performing surgery
Health Lab
U-M Health performs its first heart transplant after cardiac death
As the number of heart transplants performed across the United States continues to grow, surgeons at the U-M Health are taking advantage of technology that could increase its transplant yield by as much as 30%. Transplant surgeons in Ann Arbor completed the health system’s first heart transplant using an organ from a donor who had recently died — a process called donation after circulatory death, or DCD.
older man on cpap machine sitting on bed
Health Lab
Controlling elevated carbon dioxide improves survival
A Michigan Medicine study finds controlling elevated carbon dioxide improves survival in patients.